Published in Antimicrob Agents Chemother on May 25, 2007
Different classes of antibiotics differentially influence shiga toxin production. Antimicrob Agents Chemother (2010) 1.70
Effects of antibiotics on Shiga toxin 2 production and bacteriophage induction by epidemic Escherichia coli O104:H4 strain. Antimicrob Agents Chemother (2012) 1.62
Shiga toxin-producing Escherichia coli O104:H4: a new challenge for microbiology. Appl Environ Microbiol (2012) 1.39
Regulation of a muralytic enzyme by dynamic membrane topology. Nat Struct Mol Biol (2009) 1.04
Shigatoxin-associated hemolytic uremic syndrome: current molecular mechanisms and future therapies. Drug Des Devel Ther (2012) 0.86
Symptoms and clinical course of EHEC O104 infection in hospitalized patients: a prospective single center study. PLoS One (2013) 0.84
Phenethyl isothiocyanate inhibits shiga toxin production in enterohemorrhagic Escherichia coli by stringent response induction. Antimicrob Agents Chemother (2014) 0.79
Different Effects of Six Antibiotics and Ten Traditional Chinese Medicines on Shiga Toxin Expression by Escherichia coli O157:H7. Evid Based Complement Alternat Med (2013) 0.76
A Rapid Immunoassay for Detection of Shiga Toxin-Producing Escherichia coli Directly from Human Fecal Samples and Its Performance in Detection of Toxin Subtypes. J Clin Microbiol (2016) 0.75
Complete genome sequence of enterohemorrhagic Escherichia coli O157:H7 and genomic comparison with a laboratory strain K-12. DNA Res (2001) 15.22
Vero response to a cytotoxin of Escherichia coli. Infect Immun (1977) 13.49
The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med (2000) 7.78
Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: a meta-analysis. JAMA (2002) 4.72
Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice. J Infect Dis (2000) 4.24
Diversification of Escherichia coli genomes: are bacteriophages the major contributors? Trends Microbiol (2001) 3.08
Functional and genetic analysis of regulatory regions of coliphage H-19B: location of shiga-like toxin and lysis genes suggest a role for phage functions in toxin release. Mol Microbiol (1998) 2.78
Genomic diversity of enterohemorrhagic Escherichia coli O157 revealed by whole genome PCR scanning. Proc Natl Acad Sci U S A (2002) 2.70
Toxin gene expression by shiga toxin-producing Escherichia coli: the role of antibiotics and the bacterial SOS response. Emerg Infect Dis (2000) 2.51
Polymerase chain reaction for diagnosis of enterohemorrhagic Escherichia coli infection and hemolytic-uremic syndrome. J Clin Microbiol (1992) 2.24
Hemolytic-uremic syndrome during an outbreak of Escherichia coli O157:H7 infections in institutions for mentally retarded persons: clinical and epidemiologic observations. J Pediatr (1990) 2.16
Shiga-toxin-converting bacteriophages. Res Microbiol (2001) 1.83
Strain-specific differences in the amount of Shiga toxin released from enterohemorrhagic Escherichia coli O157 following exposure to subinhibitory concentrations of antimicrobial agents. Eur J Clin Microbiol Infect Dis (1998) 1.77
Complete nucleotide sequence of the prophage VT2-Sakai carrying the verotoxin 2 genes of the enterohemorrhagic Escherichia coli O157:H7 derived from the Sakai outbreak. Genes Genet Syst (1999) 1.70
Comparison of Shiga toxin production by hemolytic-uremic syndrome-associated and bovine-associated Shiga toxin-producing Escherichia coli isolates. Appl Environ Microbiol (2003) 1.65
Shiga-like toxin converting phage of enterohemorrhagic Escherichia coli strain 933. Microb Pathog (1989) 1.60
Isogenic lysogens of diverse shiga toxin 2-encoding bacteriophages produce markedly different amounts of shiga toxin. Infect Immun (1999) 1.53
Diversity of stx2 converting bacteriophages induced from Shiga-toxin-producing Escherichia coli strains isolated from cattle. Microbiology (2004) 1.53
Shiga toxin 2-converting bacteriophages associated with clonal variability in Escherichia coli O157:H7 strains of human origin isolated from a single outbreak. Infect Immun (2003) 1.47
Nonpathogenic Escherichia coli can contribute to the production of Shiga toxin. Infect Immun (2003) 1.44
A surface of Escherichia coli sigma 70 required for promoter function and antitermination by phage lambda Q protein. Genes Dev (1998) 1.29
Diversity and host range of Shiga toxin-encoding phage. Infect Immun (2004) 1.20
Effect of antimicrobial agents, especially fosfomycin, on the production and release of Vero toxin by enterohaemorrhagic Escherichia coli O157:H7. FEMS Immunol Med Microbiol (1997) 1.17
Sequence analysis of Stx2-converting phage VT2-Sa shows a great divergence in early regulation and replication regions. DNA Res (1999) 1.08
Commensal bacteria influence Escherichia coli O157:H7 persistence and Shiga toxin production in the mouse intestine. Infect Immun (2006) 1.06
Effects of repeated subculturing and prolonged storage at room temperature of enterohemorrhagic Escherichia coli O157:H7 on pulsed-field gel electrophoresis profiles. J Clin Microbiol (2002) 1.06
Differential inhibition of transcription from sigma70- and sigma32-dependent promoters by rifampicin. FEBS Lett (1998) 1.02
Low-level release of Shiga-like toxin (verocytotoxin) and endotoxin from enterohemorrhagic Escherichia coli treated with imipenem. Antimicrob Agents Chemother (1997) 0.96
Genetic structure and chromosomal integration site of the cryptic prophage CP-1639 encoding Shiga toxin 1. Microbiology (2005) 0.95
Genetic characterization of Escherichia coli O157: H7/- strains carrying the stx2 gene but not producing Shiga toxin 2. Microbiol Immunol (2006) 0.95
Effect of subinhibitory concentrations of antimicrobial agents (quinolones and macrolide) on the production of verotoxin by enterohemorrhagic Escherichia coli O157:H7. Can J Microbiol (1999) 0.95
Macrolides and clindamycin suppress the release of Shiga-like toxins from Escherichia coli O157:H7 in vitro. Int J Antimicrob Agents (2000) 0.91
Effects of azithromycin on shiga toxin production by Escherichia coli and subsequent host inflammatory response. Antimicrob Agents Chemother (2002) 0.88
Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature (2005) 5.50
HCV persistence and immune evasion in the absence of memory T cell help. Science (2003) 5.23
Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol (2013) 4.57
Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med (2010) 4.28
Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med (2003) 4.20
Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins. Ann Neurol (2009) 3.69
Follistatin gene delivery enhances muscle growth and strength in nonhuman primates. Sci Transl Med (2009) 2.21
Detection of diarrheagenic Escherichia coli by use of melting-curve analysis and real-time multiplex PCR. J Clin Microbiol (2008) 2.11
Age-related susceptibility to infection with diarrheagenic Escherichia coli among infants from Periurban areas in Lima, Peru. Clin Infect Dis (2009) 2.09
Noninvasive electroanatomic mapping of human ventricular arrhythmias with electrocardiographic imaging. Sci Transl Med (2011) 2.08
Cell-mediated immunity and the outcome of hepatitis C virus infection. Annu Rev Microbiol (2004) 2.03
Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. Ann Neurol (2010) 2.02
Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy. Ann Neurol (2010) 1.81
Limited T cell receptor diversity of HCV-specific T cell responses is associated with CTL escape. J Exp Med (2004) 1.79
Clinical benefits of remote versus transtelephonic monitoring of implanted pacemakers. J Am Coll Cardiol (2009) 1.78
Atrial fibrillation in the elderly. Am J Med (2007) 1.74
Mutational escape from CD8+ T cell immunity: HCV evolution, from chimpanzees to man. J Exp Med (2005) 1.69
Loss of immune escape mutations during persistent HCV infection in pregnancy enhances replication of vertically transmitted viruses. Nat Med (2013) 1.65
Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies. J Virol (2010) 1.55
Implantable cardioverter-defibrillator therapy improves long-term survival in patients with unexplained syncope, cardiomyopathy, and a negative electrophysiologic study. Heart Rhythm (2005) 1.48
Smokers are at markedly increased risk of appropriate defibrillator shocks in a primary prevention population. Heart Rhythm (2006) 1.43
Quantitative real-time polymerase chain reaction for enteropathogenic Escherichia coli: a tool for investigation of asymptomatic versus symptomatic infections. Clin Infect Dis (2011) 1.42
Magnetic guidance system for cardiac electrophysiology: a prospective trial of safety and efficacy in humans. J Am Coll Cardiol (2003) 1.40
High frequency of antimicrobial drug resistance of diarrheagenic Escherichia coli in infants in Peru. Am J Trop Med Hyg (2009) 1.38
Acute hepatitis A virus infection is associated with a limited type I interferon response and persistence of intrahepatic viral RNA. Proc Natl Acad Sci U S A (2011) 1.36
Persistent expression of FLAG-tagged micro dystrophin in nonhuman primates following intramuscular and vascular delivery. Mol Ther (2009) 1.35
Regulation of Na+ channels in lung alveolar type II epithelial cells. Proc Am Thorac Soc (2004) 1.24
Stable cytotoxic T cell escape mutation in hepatitis C virus is linked to maintenance of viral fitness. PLoS Pathog (2008) 1.24
Silencing of T lymphocytes by antigen-driven programmed death in recombinant adeno-associated virus vector-mediated gene therapy. Blood (2008) 1.24
Conserved hierarchy of helper T cell responses in a chimpanzee during primary and secondary hepatitis C virus infections. J Immunol (2004) 1.21
Gene therapy for muscular dystrophy: lessons learned and path forward. Neurosci Lett (2012) 1.16
Escape mutations alter proteasome processing of major histocompatibility complex class I-restricted epitopes in persistent hepatitis C virus infection. J Virol (2005) 1.15
Imaging of the diaphragm: anatomy and function. Radiographics (2012) 1.13
p53 mutations in human aggressive and nonaggressive basal and squamous cell carcinomas. Clin Cancer Res (2003) 1.13
Poor prognosis for patients with chronic kidney disease despite ICD therapy for the primary prevention of sudden death. Pacing Clin Electrophysiol (2007) 1.12
Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1). Proc Natl Acad Sci U S A (2013) 1.10
Epidemiology and spectrum of disease of Escherichia coli O157. Curr Opin Infect Dis (2003) 1.10
Global rise in human infectious disease outbreaks. J R Soc Interface (2014) 1.07
Efficacy of hepatitis B vaccine against antiviral drug-resistant hepatitis B virus mutants in the chimpanzee model. Hepatology (2009) 1.07
Anti-dystrophin T cell responses in Duchenne muscular dystrophy: prevalence and a glucocorticoid treatment effect. Hum Gene Ther (2013) 1.06
"Reversed halo sign". J Thorac Imaging (2011) 1.05
Effect of lactoferrin on enteric pathogens. Biochimie (2008) 1.05
Dominance of the CD4(+) T helper cell response during acute resolving hepatitis A virus infection. J Exp Med (2012) 1.04
Detailed characterization of the peptide binding specificity of five common Patr class I MHC molecules. Immunogenetics (2006) 1.03
Variable patterns of programmed death-1 expression on fully functional memory T cells after spontaneous resolution of hepatitis C virus infection. J Virol (2008) 1.03
Lactoferrin impairs type III secretory system function in enteropathogenic Escherichia coli. Infect Immun (2003) 1.03
Selection-driven immune escape is not a significant factor in the failure of CD4 T cell responses in persistent hepatitis C virus infection. Hepatology (2010) 1.03
The azygos defibrillator lead for elevated defibrillation thresholds: implant technique, lead stability, and patient series. Pacing Clin Electrophysiol (2008) 1.03
Cross-reactive recognition of human and primate cytomegalovirus sequences by human CD4 cytotoxic T lymphocytes specific for glycoprotein B and H. Eur J Immunol (2004) 1.02
Characterization of HCV-specific Patr class II restricted CD4+ T cell responses in an acutely infected chimpanzee. Hepatology (2003) 1.01
Radiofrequency ablation of atrioventricular nodal reentrant tachycardia using a novel magnetic guidance system compared with a conventional approach. Heart Rhythm (2006) 1.00
The origin of quasispecies: cause or consequence of chronic hepatitis C viral infection? J Hepatol (2005) 0.99
Class I molecules with similar peptide-binding specificities are the result of both common ancestry and convergent evolution. Immunogenetics (2003) 0.98
Effect of lactoferrin on enteroaggregative E. coli (EAEC). Biochem Cell Biol (2006) 0.97
Human milk secretory antibodies against attaching and effacing Escherichia coli antigens. Emerg Infect Dis (2003) 0.97
Clinical studies of lactoferrin in children. Biochem Cell Biol (2012) 0.96
Lactoferrin protects rabbits from Shigella flexneri-induced inflammatory enteritis. Infect Immun (2002) 0.96
Randomized double-blind controlled trial of bovine lactoferrin for prevention of diarrhea in children. J Pediatr (2012) 0.96
Investigating the limit of detectability of a positron emission mammography device: a phantom study. Med Phys (2011) 0.95
Human lactoferrin impairs virulence of Shigella flexneri. J Infect Dis (2002) 0.93
Transmission of clonal hepatitis C virus genomes reveals the dominant but transitory role of CD8⁺ T cells in early viral evolution. J Virol (2011) 0.93
Evolution of a cell culture-derived genotype 1a hepatitis C virus (H77S.2) during persistent infection with chronic hepatitis in a chimpanzee. J Virol (2014) 0.93
Feasibility and safety of systemic rAAV9-hNAGLU delivery for treating mucopolysaccharidosis IIIB: toxicology, biodistribution, and immunological assessments in primates. Hum Gene Ther Clin Dev (2014) 0.91
Impact of lactoferrin supplementation on growth and prevalence of Giardia colonization in children. Clin Infect Dis (2008) 0.91
Management of children with infection-associated persistent diarrhea. Semin Pediatr Infect Dis (2004) 0.91
Analysis of the TCR beta variable gene repertoire in chimpanzees: identification of functional homologs to human pseudogenes. J Immunol (2003) 0.91
Human pDCs preferentially sense enveloped hepatitis A virions. J Clin Invest (2014) 0.89
Empyema necessitans and acute osteomyelitis associated with community-acquired methicillin-resistant Staphylococcus aureus in an infant. Biomedica (2009) 0.89
A novel multivalent human CTL peptide construct elicits robust cellular immune responses in HLA-A*0201 transgenic mice: implications for HTLV-1 vaccine design. Vaccine (2003) 0.89
Fecal leukocytes in children infected with diarrheagenic Escherichia coli. J Clin Microbiol (2011) 0.88
Multiplex real-time PCR (MRT-PCR) for diarrheagenic. Methods Mol Biol (2013) 0.88
Images in cardiovascular medicine. Right ventricular lead perforation presenting as left chest wall muscle stimulation. Circulation (2005) 0.87
"Septal bounce". J Thorac Imaging (2012) 0.86
Evidence-based medicine training in a resource-poor country, the importance of leveraging personal and institutional relationships. J Eval Clin Pract (2011) 0.86
Radial spectroscopic MRI of hyperpolarized [1-(13) C] pyruvate at 7 tesla. Magn Reson Med (2013) 0.86
T-cell immunity and hepatitis C virus reinfection after cure of chronic hepatitis C with an interferon-free antiviral regimen in a chimpanzee. Hepatology (2014) 0.85
Pretravel health advice among international travelers visiting Cuzco, Peru. J Travel Med (2005) 0.84
Effect of bovine lactoferrin in Salmonella ser. Typhimurium infection in mice. Biometals (2010) 0.82
Kinetic analysis by real-time PCR of hepatitis C virus (HCV)-specific T cells in peripheral blood and liver after challenge with HCV. J Virol (2008) 0.82
Imaging features of thoracic metastases from gynecologic neoplasms. Radiographics (2014) 0.82
Altered systemic ketone body metabolism in advanced heart failure. Tex Heart Inst J (2011) 0.81
Evaluation of prolonged fatigue post-West Nile virus infection and association of fatigue with elevated antiviral and proinflammatory cytokines. Viral Immunol (2014) 0.81
Mutational escape of CD8+ T cell epitopes: implications for prevention and therapy of persistent hepatitis virus infections. Med Microbiol Immunol (2014) 0.80
Continuous CD8⁺ T-cell priming by dendritic cell cross-presentation of persistent antigen following adeno-associated virus-mediated gene delivery. J Virol (2011) 0.80
Ethanol and aloe emodin alter the p53 mutational spectrum in ultraviolet radiation-induced murine skin tumors. Mol Carcinog (2004) 0.79
Continuous ECGI mapping of spontaneous VT initiation, continuation, and termination with antitachycardia pacing. Heart Rhythm (2012) 0.79
Case records of the Massachusetts General Hospital. Case 22-2014. A 40-year-old woman with postpartum dyspnea and hypoxemia. N Engl J Med (2014) 0.79
Use of lutein and zeaxanthin alone or combined with Brilliant Blue to identify intraocular structures intraoperatively. Retina (2012) 0.79
Shiga toxin-producing Escherichia coli in Peruvian children with bloody diarrhea. Pediatr Infect Dis J (2012) 0.78
Detection of secretory immunoglobulin A in human colostrum as mucosal immune response against proteins of the type III secretion system of Salmonella, Shigella and enteropathogenic Escherichia coli. Pediatr Infect Dis J (2013) 0.78
Protective efficacy of multiepitope human leukocyte antigen-A*0201 restricted cytotoxic T-lymphocyte peptide construct against challenge with human T-cell lymphotropic virus type 1 Tax recombinant vaccinia virus. J Acquir Immune Defic Syndr (2004) 0.78
Feasibility of multianimal hyperpolarized (13) C MRS. Magn Reson Med (2014) 0.78
Lactoferrin blocks the initial host cell attachment mechanism of Enteropathogenic E. coli (EPEC). Adv Exp Med Biol (2004) 0.77
Systolic anterior motion of the mitral valve. J Thorac Imaging (2012) 0.76
Development of a multiple gas analyzer using cavity ringdown spectroscopy for use in advanced fire detection. Appl Opt (2009) 0.76
Will there be a vaccine to protect against the hepatitis C virus? Gastroenterology (2012) 0.75
Reply: To PMID 22733932. AJR Am J Roentgenol (2013) 0.75
Poliomyelitis-like syndrome in a child with West Nile virus infection. Pediatr Infect Dis J (2004) 0.75